Winston E. Abara, MD, PhD; Amir Qaseem, MD, PhD, MHA; Sarah Schillie, MD, MPH, MBA; Brian J. McMahon, MD; Aaron M. Harris, MD, MPH (*); for the High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention
Disclaimer: The conclusions, findings, and opinions expressed by the authors do not necessarily reflect the official position of the Centers for Disease Control and Prevention.
Financial Support: Financial support for the development of this paper comes exclusively from the ACP operating budget.
Disclosures: Dr. McMahon reports that the program he works in, the Alaska Native Tribal Health Consortium Liver Disease and Hepatitis Program (a nonprofit managed care system serving American Indians and Alaska Natives), has 2 research grants from Gilead Sciences for hepatitis C treatment. Dr. McMahon is not an investigator listed on these grants but does see patients who receive free hepatitis C medications supplied by Gilead Sciences in the course of his patient care duties. Dr. Lohr reports that he is the Treasurer of the American College of Physicians. Dr. McLean reports personal fees from Takeda Pharmaceuticals outside the submitted work and is a member of the American College of Physicians Clinical Guidelines Committee and the American College of Rheumatology Quality of Care Committee. Authors not named here have disclosed no conflicts of interest. Authors followed the policy regarding conflicts of interest described at www.annals.org/article.aspx?articleid=745942. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-1106. All financial and intellectual disclosures of interest were declared and potential conflicts were discussed and managed. No individuals were recused from discussion or voting due to conflicts of interest. A record of disclosures of interest is kept for each High Value Care Task Force meeting and conference call and can be viewed at www.acponline.org/clinical-information/high-value-care.
Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that she has no financial relationships or interests to disclose. Darren B. Taichman, MD, PhD, Executive Deputy Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Pfizer and Johnson & Johnson.
Requests for Single Reprints: Amir Qaseem, MD, PhD, MHA, American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Abara, Schillie, and Harris: Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, MS G-37, Atlanta, GA 30333.
Dr. Qaseem: American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106.
Dr. McMahon: Arctic Investigations Program, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 4055 Tudor Center Drive, Anchorage, AK 99508.
Author Contributions: Conception and design: W.E. Abara, A. Qaseem, B.J. McMahon, A.M. Harris, D.M. DeLong, A.M. López, R.M. McLean.
Analysis and interpretation of the data: W.E. Abara, A. Qaseem, B.J. McMahon, A.M. Harris, R. Centor, J.A. Jokela, A.M. López, R.M. McLean.
Drafting of the article: W.E. Abara, A. Qaseem, B.J. McMahon, A.M. Harris.
Critical revision of the article for important intellectual content: W.E. Abara, S. Schillie, B.J. McMahon, A.M. Harris, G.M. Abraham, R. Centor, D.M. DeLong, L.L. Humphrey, J.A. Jokela, R.H. Lohr, A.M. López, R.M. McLean.
Final approval of the article: W.E. Abara, A. Qaseem, S. Schillie, B.J. McMahon, A.M. Harris, G.M. Abraham, R. Centor, D.M. DeLong, H.E. Gantzer, C.A. Horwitch, L.L. Humphrey, J.A. Jokela, J.M.W. Li, R.H. Lohr, A.M. López, R.M. McLean.
Statistical expertise: A. Qaseem.
Obtaining of funding: A. Qaseem.
Administrative, technical, or logistic support: W.E. Abara, A. Qaseem, A.M. Harris.
Collection and assembly of data: W.E. Abara, A.M. Harris.
Vaccination, screening, and linkage to care can reduce the burden of chronic hepatitis B virus (HBV) infection. However, recommendations vary among organizations, and their implementation has been suboptimal. The American College of Physicians' High Value Care Task Force and the Centers for Disease Control and Prevention developed this article to present best practice statements for hepatitis B vaccination, screening, and linkage to care.
A narrative literature review of clinical guidelines, systematic reviews, randomized trials, and intervention studies on hepatitis B vaccination, screening, and linkage to care published between January 2005 and June 2017 was conducted.
Clinicians should vaccinate against hepatitis B virus (HBV) in all unvaccinated adults (including pregnant women) at risk for infection due to sexual, percutaneous, or mucosal exposure; health care and public safety workers at risk for blood exposure; adults with chronic liver disease, end-stage renal disease (including hemodialysis patients), or HIV infection; travelers to HBV-endemic regions; and adults seeking protection from HBV infection.
Clinicians should screen (hepatitis B surface antigen, antibody to hepatitis B core antigen, and antibody to hepatitis B surface antigen) for HBV in high-risk persons, including persons born in countries with 2% or higher HBV prevalence, men who have sex with men, persons who inject drugs, HIV-positive persons, household and sexual contacts of HBV-infected persons, persons requiring immunosuppressive therapy, persons with end-stage renal disease (including hemodialysis patients), blood and tissue donors, persons infected with hepatitis C virus, persons with elevated alanine aminotransferase levels (≥19 IU/L for women and ≥30 IU/L for men), incarcerated persons, pregnant women, and infants born to HBV-infected mothers.
Clinicians should provide or refer all patients identified with HBV (HBsAg-positive) for posttest counseling and hepatitis B–directed care.
Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM, . Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017;167:794–804. doi: 10.7326/M17-1106
Download citation file:
Published: Ann Intern Med. 2017;167(11):794-804.
Published at www.annals.org on 21 November 2017
Gastroenterology/Hepatology, Guidelines, Infectious Disease, Prevention/Screening, Vaccines/Immunization.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use